| Literature DB >> 24391118 |
Johann K Hitzler1, Wensheng He, John Doyle, Mitchell Cairo, Bruce M Camitta, Ka Wah Chan, Miguel A Diaz Perez, Christopher Fraser, Thomas G Gross, John T Horan, Alana A Kennedy-Nasser, Carrie Kitko, Joanne Kurtzberg, Leslie Lehmann, Tracey O'Brien, Michael A Pulsipher, Franklin O Smith, Mei-Jie Zhang, Mary Eapen, Paul A Carpenter.
Abstract
We report on 27 patients with Down syndrome (DS) and acute lymphoblastic leukemia (ALL) who received allogeneic hematopoietic cell transplantation (HCT) between 2000 and 2009. Seventy-eight percent of patients received myeloablative conditioning and 52% underwent transplantation in second remission. Disease-free survival (DFS) was 24% at a median of 3 years. Post-transplant leukemic relapse was more frequent than expected for children with DS-ALL (54%) than for non-DS ALL. These data suggest leukemic relapse rather than transplant toxicity is the most important cause of treatment failure. Advancements in leukemia control are especially needed for improvement in HCT outcomes for DS-ALL.Entities:
Keywords: Down syndrome; acute lymhoblastic leukemia; hematopoietic stem cell transplantation; pediatric; relapse; trisomy 21
Mesh：
Substances：
Year: 2014 PMID： 24391118 PMCID： PMC4080799 DOI： 10.1002/pbc.24918
Source DB: PubMed Journal: Pediatr Blood Cancer ISSN： 1545-5009 Impact factor: 3.167